08:00 , Dec 4, 2000 |  BioCentury  |  Finance

Trailing indicator

Biotech somehow still is managing to avoid the hammering put on the broader NASDAQ market. Although the BioCentury 100 is down 4 percent over the last two weeks and stands down 19 percent since the...
07:00 , Oct 2, 2000 |  BioCentury  |  Finance

Bio-equity sizzles

All was well in biotech last week, even as the tech-heavy NASDAQ Composite shed 3 percent. The BioCentury 100 traded up 2 percent, while $856.3 million was raised in six underwritten deals that included a...
07:00 , Sep 28, 2000 |  BC Extra  |  Financial News

FibroGen raises $56.5 million

FibroGen (South San Francisco, Calif.) raised $56.5 million in a venture financing. Investors included Franklin Templeton Investments; American Express Financial Advisors; BioFund Ventures; Life Sciences Venture Fund; Hotung Ventures; IBJ Investments; ORIX; Asahi Life; and...
07:00 , Jul 26, 2000 |  BC Extra  |  Financial News

Third Wave raises $48 million

Third Wave (Madison, Wis.), which is developing the Invader SNP detection system, raised $48 million in a private round. Investors included BB Biotech; Janus Capital; Putnam Investments; American Express; Scudder Funds; Invesco Funds Group; Tisch...
07:00 , Apr 11, 2000 |  BC Extra  |  Financial News

diaDexus raises $102.5 million

Genomics biomarker play diaDexus (Santa Clara, Calif.) raised $102.5 million in a private placement of series C preferred stock led by BA Venture Partners; and American Express Financial. Prudential Vector acted as the placement agent....
07:00 , Jul 26, 1999 |  BioCentury  |  Finance

Top Centocor shareholders

Top Centocor shareholders Investor 3/31 position Chg from 12/31 Primecap Management (A) 7,954,400 (B) 4,323,300 Iridian Asset Management 4,267,400 1,354,600 Putnam Investment Management 4,147,831 -5,747,458 Fidelity Management & Research 2,075,800 -392,630 Neuberger Berman 1,808,140 1,696,000...
07:00 , Jun 21, 1999 |  BioCentury  |  Finance

Goodwill games

If Roche surprised Wall Street earlier this month with its plans to buy out Genentech and then sell some of it back on the equity market, equally clever are the pharma company's plans to leave...